Ultragenyx (RARE) investor relations material

Introduction and purpose

• FDA approved FAYUVI, the first treatment for Sanfilippo syndrome type A, marking a major milestone for patients and families affected by this fatal neurodegenerative disease.

• The approval follows years of advocacy, research, and collaboration among families, clinicians, and organizations in the MPS community.

• Approval marks a historic milestone for the patient community and is the second gene therapy approval for the company.

Details of approval or decision

• FAYUVI is indicated for pediatric patients with preserved neurodevelopmental function and covers the entire pediatric age range with MPS IIIA.

• Approval was granted as a standard full approval, not accelerated, due to robust clinical data from the pivotal Transpher A trial and long-term follow-up.

• The company received a priority review voucher with the approval.

Impact on industry and stakeholders

• FAYUVI offers hope to families previously without treatment options and is expected to alter the disease course, addressing a significant unmet need.

• The launch leverages existing infrastructure, minimizing incremental expenses and accelerating patient access.

• Approval is expected to stimulate further investment in ultra-rare gene therapies.

• UltraCare® program will support patient access and navigation of insurance and treatment logistics.